Sandoz Accuses Eli Lilly Of Inequitable Conduct
Generic pharmaceutical company Sandoz Inc. is fighting back against Eli Lilly & Co. in an infringement battle over a patent for attention-deficit hyperactivity disorder treatment Strattera, denying the drug maker's claims...To view the full article, register now.
Already a subscriber? Click here to view full article